All of the above-mentioned evidence provided the rationale for combining epigenetic drugs and ICIs in melanoma patients; moreover, in the preclinical setting, the combination of HDAC-i and immunotherapeutic agents—or adoptive T-cell transfer—has yielded promising results in melanoma models [97,98,99]. This evidence concerns the gene HDAC9 and melanoma.